Read by QxMD icon Read

Breast Cancer Research and Treatment

Alex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, Aurélie Ayme, Solène De Talhouet, Jean-Damien Combes, Julien Peron, Alexandre Bodmer, Sophie Giraud, Adrien Buisson, Valerie Bonadona, Isabelle Gauchat-Bouchardy, Olivier Tredan, Pierre O Chappuis, S Intidhar Labidi-Galy
PURPOSE: BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy. METHODS: We included women with primary breast cancers screened for BRCA1/BRCA2 germline mutations and treated with (neo)adjuvant chemotherapy in Geneva (Swiss cohort). The primary endpoint was the incidence of febrile neutropenia following the first chemotherapy cycle (C1)...
January 11, 2019: Breast Cancer Research and Treatment
H S Rugo, R S Finn, V Diéras, J Ettl, O Lipatov, A A Joy, N Harbeck, A Castrellon, S Iyer, D R Lu, A Mori, E R Gauthier, C Huang Bartlett, K A Gelmon, D J Slamon
PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole...
January 10, 2019: Breast Cancer Research and Treatment
Seyed-Mehdi Hashemi, Abbas Balouchi, Adhra Al-Mawali, Hosein Rafiemanesh, Khadije Rezaie-Keikhaie, Salehoddin Bouya, Behroz Dehghan, Mansoureh Ashghali Farahani
PURPOSE: Breast cancer is the most common type of cancer in women around the world, and this applies to the Middle East as well. The goal of all medical care and treatment is to improve the quality of life (QoL) of patients. Accordingly, the present study aimed at evaluating the QoL of patients with breast cancer in the Middle East region. METHODS: In this meta-analysis, three electronic databases (PubMed, Web of Science, and Scopus) were searched from inception until August 2018...
January 10, 2019: Breast Cancer Research and Treatment
Ramy Gadalla, Hebatallah Hassan, Sherif Abdelaziz Ibrahim, Mahmoud Salah Abdullah, Ahmed Gaballah, Burkhard Greve, Somaya El-Deeb, Mohamed El-Shinawi, Mona Mostafa Mohamed
PURPOSE: Plasmacytoid dendritic cells (PDCs) infiltration into breast cancer tissues is associated with poor prognosis. Also, CXCR4 shows compelling evidences to be exploited by cancer cells to migrate to distant sites. The present study investigated lymph node metastasis in the light of PDCs infiltration and the potential cross talk with CXCR4/SDF-1 chemokine axis. METHODS: We assessed circulating PDCs proportions drained from the axillary tributaries, and the in situ expression of both CD303 and CXCR4 in breast cancer patients with positive lymph nodes (pLN) and negative lymph nodes (nLN) using immunohistochemistry and flow cytometry...
January 10, 2019: Breast Cancer Research and Treatment
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H Kreipe, Nadia Harbeck
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H...
January 10, 2019: Breast Cancer Research and Treatment
Elisabeth Specht Stovgaard, Anne Dyhl-Polk, Anne Roslind, Eva Balslev, Dorte Nielsen
PURPOSE: To systematically review the literature on the expression of PD-L1 in primary BC, variation of expression between subtypes and effect on overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS). Additionally, for studies in the neoadjuvant setting, we have reviewed the ability of PD-L1 to predict pathological complete response (pCR). METHODS: Articles included in this review were retrieved by searching PubMed (1966-2018) and EMBASE (1980-2018)...
January 10, 2019: Breast Cancer Research and Treatment
Anna R Gagliardi, Frances C Wright, Nicole J Look Hong, Gary Groot, Lucy Helyer, Pamela Meiers, May Lynn Quan, Robin Urquhart, Rebecca Warburton
PURPOSE: The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS: Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older were nominated. Forty-six recommendations to support PCC for DCIS were derived from primary research, and rated in a two-round Delphi process from March to June 2018...
January 9, 2019: Breast Cancer Research and Treatment
G M Clarke, C M B Holloway, J T Zubovits, S Nofech-Mozes, M Murray, K Liu, D Wang, A Kiss, M J Yaffe
PURPOSE: Linear tumor size (T-size) estimated with conventional histology informs breast cancer management. Previously we demonstrated significant differences in margin and focality estimates using conventional histology versus digital whole-mount serial sections (WMSS). Using WMSS we can measure T-size or volume. Here, we compare WMSS T-size with volume, and with T-size measured conventionally. We also compare the ellipsoid model for calculating tumor volume to direct, WMSS measurement...
January 5, 2019: Breast Cancer Research and Treatment
Jan Lubinski, Tomasz Huzarski, Jacek Gronwald, Cezary Cybulski, Tadeusz Debniak, Ping Sun, Shana J Kim, Joanne Kotsopoulos, Steven A Narod
PURPOSE: Women with an inherited germline BRCA1 mutation have a high lifetime risk of developing breast cancer. We have previously shown that, among BRCA mutation carriers, incidence rates of breast cancer vary by country of residence. METHODS: In the current study, we prospectively calculated the cumulative and annual incidence rates of incident breast cancer, contralateral breast cancer and ipsilateral breast cancer recurrence among BRCA1 mutation carriers in Poland...
January 5, 2019: Breast Cancer Research and Treatment
C D Savci-Heijink, H Halfwerk, G K J Hooijer, J Koster, H M Horlings, S L Meijer, M J van de Vijver
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases. METHODS: mRNA expression profiles of primary breast carcinoma samples (n = 151) from patients who developed metastatic disease were analyzed and EMT status was designated using a previously described EMT-core signature...
January 4, 2019: Breast Cancer Research and Treatment
I M Alhudiri, C C Nolan, I O Ellis, A Elzagheid, E A Rakha, Andrew R Green, C J Chapman
PURPOSE: Lamins A/C, a major component of the nuclear lamina, play key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of poor prognosis. However, its clinical significance in breast cancer remains to be defined. This study aimed to evaluate expression and prognostic significance of lamin A/C in early-stage breast cancer. METHODS: Using immunohistochemical staining of tissue microarrays, expression of lamin A/C was evaluated in a large well-characterised series of early-stage operable breast cancer (n = 938) obtained from Nottingham Primary Breast Carcinoma Series...
January 4, 2019: Breast Cancer Research and Treatment
Marissa L G Vane, Maria A Willemsen, Lori M van Roozendaal, Sander M J van Kuijk, Loes F S Kooreman, Sabine Siesling, Hans H W de Wilt, Marjolein L Smidt
OBJECTIVE: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1-2 positive SLN(s). METHODS: All cT1-2N0 breast cancer patients with 1-3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry...
January 4, 2019: Breast Cancer Research and Treatment
A Ramsay Bowden, Marc Tischkowitz
BACKGROUND: The identification of new hereditary breast cancer genes is an area of highly active research. In 2015, two independent studies provided initial evidence for a novel breast cancer susceptibility gene, RECQL, a DNA helicase which plays an important role in the DNA damage response. Several subsequent studies in independent patient cohorts have provided further data on RECQL variant frequency in additional populations, some of which have brought in to question the increased breast cancer risk associated with RECQL mutations...
January 4, 2019: Breast Cancer Research and Treatment
Patrick H Dinkelborg, Meng Wang, Liliana Gheorghiu, Joseph M Gurski, Theodore S Hong, Cyril H Benes, Dejan Juric, Rachel B Jimenez, Kerstin Borgmann, Henning Willers
PURPOSE: Triple-negative breast cancers (TNBC) are often resistant to treatment with ionizing radiation (IR). We sought to investigate whether pharmacologic inhibition of Chk1 kinase, which is commonly overexpressed in TNBC, preferentially sensitizes TNBC cells to IR. METHODS: Ten breast cancer cell lines were screened with small molecule inhibitors against Chk1 and other kinases. Chk1 inhibition was also tested in isogenic KRAS mutant or wild-type cancer cells...
January 3, 2019: Breast Cancer Research and Treatment
Andrea M Austin, Nirav S Kapadia, Gabriel A Brooks, Tracy L Onega, A Heather Eliassen, Rulla M Tamimi, Michelle Holmes, Qianfei Wang, Francine Grodstein, Anna N A Tosteson
PURPOSE: Increasingly epidemiological cohorts are being linked to claims data to provide rich data for healthcare research. These cohorts tend to be different than the general United States (US) population. We will analyze healthcare utilization of Nurses' Health Study (NHS) participants to determine if studies of newly diagnosed incident early-stage breast cancer can be generalized to the broader US Medicare population. METHODS: Analytic cohorts of fee-for-service NHS-Medicare-linked participants and a 1:13 propensity-matched SEER-Medicare cohort (SEER) with incident breast cancer in the years 2007-2011 were considered...
January 3, 2019: Breast Cancer Research and Treatment
Takuro Yamamoto, Noriko Kanaya, George Somlo, Shiuan Chen
PURPOSE: Palbociclib is an approved cyclin-dependent kinase (CDK) 4/6 inhibitor for treatment of patients with ER-positive and HER2-negative breast cancers. While Retinoblastoma protein (pRb), a major substrate of CDK4/6, is a potential target in triple negative breast cancer (TNBC), the usefulness of CDK4/6 inhibitors in this cancer has not been established. This preclinical study investigated the combination effects of palbociclib and the dual mammalian target of rapamycin (mTOR) kinase inhibitor MLN0128 in estrogen receptor (ER)-negative breast cancer in vitro and in vivo...
January 3, 2019: Breast Cancer Research and Treatment
Ziguo Yang, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Juan Zhang, Yuntao Xie
PURPOSE: The ataxia telangiectasia-mutated (ATM) gene is a moderate susceptibility gene for breast cancer. However, little is known about the breast cancer phenotypes associated with ATM mutation. We therefore investigated the spectrum and clinical characteristics of ATM germline mutations in Chinese breast cancer patients. METHODS: A multi-gene panel was performed to screen for ATM germline mutations in 7657 BRCA1/2-negative breast cancer patients. All deleterious mutations were validated by independent polymerase chain reaction (PCR)-Sanger sequencing...
January 3, 2019: Breast Cancer Research and Treatment
Seiichi Imanishi, Yasuto Naoi, Kenzo Shimazu, Masafumi Shimoda, Naofumi Kagara, Tomonori Tanei, Tomohiro Miyake, Seung Jin Kim, Shinzaburo Noguchi
PURPOSE: This study aimed to elucidate the clinicopathological characteristics of breast tumors with homologous recombination deficiency (HRD) and the sensitivity to neoadjuvant paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (P-FEC). METHODS: Tumor biopsy samples obtained before P-FEC from 141 patients with stages II-III breast cancer including the luminal (n = 76), luminal-HER2 (n = 13), HER2 (n = 17), and triple-negative (TNBC, n = 35) subtypes were subjected to assay for HRD score using the OncoScan CNV FFPE Assay Kit...
January 3, 2019: Breast Cancer Research and Treatment
Daniel Ben Lustig, Rebecca Warburton, Carol K Dingee, Urve Kuusk, Jin-Si Pao, Elaine C McKevitt
PURPOSE: Patients with spontaneous nipple discharge (SND) who have neither clinically palpable masses nor evidence of disease on imaging with mammogram and/or ultrasound are traditionally investigated with galactogram and duct excision. As breast imaging improves, it has raised the question whether galactography and microductectomy are necessary to diagnose breast cancer. The purpose of this study was to determine the incidence of malignancy in patients presenting with SND who underwent microductectomy and to evaluate the utility of duct excision and galactography in patients whose initial clinical and radiological evaluation were negative...
January 3, 2019: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"